Hoosier Cancer Research Network: Company Profile

Background

Overview

Hoosier Cancer Research Network (HCRN), established in 1984, is an independent nonprofit contract research organization specializing in early-phase, multi-center, investigator-initiated oncology clinical trials. Operating through a nationwide network of over 100 academic and community sites, HCRN is dedicated to advancing cancer research, education, and patient advocacy.

Mission and Vision

HCRN's mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech collaborators to advance cancer research, education, and patient advocacy. The organization envisions a collaborative approach to cancer research that bridges the gap between academic institutions and community physicians, ensuring that innovative treatments reach patients nationwide.

Industry Significance

As a nonprofit contract research organization (CRO), HCRN plays a pivotal role in the oncology research landscape by facilitating multi-center clinical trials that are essential for developing new cancer therapies. Its extensive network and comprehensive study management services contribute significantly to the advancement of cancer treatment and patient care.

Key Strategic Focus

Core Objectives

Advancing Cancer Research: Conducting innovative clinical trials to develop and evaluate new cancer treatments.

Enhancing Patient Advocacy: Ensuring that research outcomes translate into improved patient care and support.

Fostering Collaboration: Building strong partnerships among academic institutions, community physicians, pharmaceutical, and biotech companies.

Areas of Specialization

HCRN specializes in early-phase, multi-center, investigator-initiated oncology clinical trials, covering a wide range of cancer types and supportive care.

Key Technologies Utilized

Electronic Data Capture (EDC): Implementing EDC systems to enhance data collection efficiency and accuracy.

Biorepository Management: Maintaining dedicated facilities for sample storage, including ambient and frozen samples.

Primary Markets Targeted

HCRN's primary focus is on the U.S. market, collaborating with over 100 academic and community sites across the country.

Financials and Funding

Funding History

As a nonprofit organization, HCRN's funding primarily comes from grants, partnerships, and collaborations with academic institutions, pharmaceutical companies, and other research entities. Specific details regarding total funds raised and recent funding rounds are not publicly disclosed.

Notable Investors

HCRN collaborates with various stakeholders, including academic institutions, pharmaceutical companies, and biotech firms, to fund and support its clinical trials. However, specific investor names are not publicly disclosed.

Utilization of Capital

The capital raised is utilized for:

Study Management: Budgeting, contracting, and regulatory support.

Clinical Operations: Site selection, training, activation, and monitoring.

Data Management: Electronic data capture, data monitoring, and safety reporting.

Correlative Research: Sample collection, processing, and storage.

Pipeline Development

Key Pipeline Candidates

HCRN manages a diverse portfolio of clinical trials across various cancer types, including:

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancer

Lymphoma

Melanoma

Myeloid Malignancies

Neuro-Oncology

Sarcoma

Thoracic Cancer

Stages of Clinical Trials

The organization conducts trials at various stages, from early-phase studies to advanced clinical trials, focusing on evaluating the safety and efficacy of new treatments.

Target Conditions

HCRN's trials address a wide range of cancers, aiming to develop and assess new therapeutic options for these conditions.

Anticipated Milestones

Specific timelines for anticipated milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

HCRN employs proprietary technologies in electronic data capture (EDC) systems and biorepository management to enhance the efficiency and accuracy of clinical trials.

Significant Scientific Methods

Electronic Data Capture (EDC): Utilizing EDC systems to streamline data collection and monitoring processes.

Biorepository Management: Implementing advanced storage solutions for biological samples to support correlative research.

Leadership Team

Executive Profiles

Cyndi Burkhardt, RN: Executive Director, leading HCRN's strategic direction and operations.

Christopher A. Fausel, PharmD, MHA, BCOP: Chairman of the Board of Directors, overseeing organizational governance.

Shadia Jalal, MD: Chief Scientific Officer, guiding the scientific and clinical research initiatives.

Key Contributions

The leadership team has been instrumental in expanding HCRN's network, enhancing operational efficiency, and fostering collaborations with academic and community institutions.

Competitor Profile

Market Insights and Dynamics

The oncology clinical trial sector is characterized by a growing emphasis on personalized medicine, increased collaboration between academic and community institutions, and the integration of advanced technologies to improve trial efficiency and patient outcomes.

Competitor Analysis

HCRN operates in a competitive landscape with several organizations offering similar services, including:

Children's Oncology Group: Focuses on pediatric cancer research and clinical trials.

Bladder Cancer Advocacy Network: Dedicated to bladder cancer research and patient support.

Lymphoma Research Foundation: Specializes in lymphoma research and education.

Strategic Collaborations and Partnerships

HCRN collaborates with various stakeholders, including academic institutions, pharmaceutical companies, and biotech firms, to fund and support its clinical trials. Notably, HCRN serves as the administrative headquarters for the Big Ten Cancer Research Consortium, enhancing its collaborative research efforts.

Operational Insights

HCRN's extensive network of over 100 academic and community sites across the United States provides a competitive advantage in patient recruitment and data collection, facilitating efficient multi-center clinical trials.

Strategic Opportunities and Future Directions

HCRN is well-positioned to leverage its collaborative network and technological infrastructure to expand its portfolio of clinical trials, particularly in emerging areas of oncology research. Future directions include enhancing patient engagement, integrating advanced data analytics, and fostering international collaborations to accelerate the development of innovative cancer therapies.